Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 19;13(9):799. doi: 10.1038/s41419-022-05247-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A KIF11 expression in CCA patient samples compared to that in normal tissue samples within the TCGA dataset. Statistical analysis was performed using the two-sided unpaired t-test. B KIF11 expression in CCA patient samples grouped based on pathological grade. Statistical analysis was performed using the two-sided unpaired t-test. C Representative images of KIF11 high- and low-expression in human CCA tumor tissue samples by immunohistochemical analysis. D The number of cases in the KIF11 low and high groups. Human CCA samples with staining scores of 0 and 1 were allocated to the KIF11 low-expression group (n = 33), whereas those with a score of 2 and 3 were allocated to the KIF11 high-expression group (n = 74). E Overall survival of CCA patients with high and low KIF11 gene expression using Kaplan-Meier survival curves. Statistical analyses were performed using the log-rank test. F Representative images of KIF11 expression in tumor, para-tumor, and normal tissues from CCA patients by immunohistochemical analysis. Arrows indicate intrahepatic bile ducts. G Expression of KIF11 in CCA cell lines and normal cell line HIBEpiC detected by immunoblotting. H The knockdown efficacy of KIF11 siRNA detected by immunoblotting. I Cell sensitivity to SB743921 treatment in control and KIF11-knockdown cells. CCLP1 and TFK1 cells transfected with indicated siRNA or NC were exposed to SB743921 for 72 h. Cell viability was measured using the CellTiter-Glo luminescent cell viability assay.